VINLON 1 MG INJ. VIAL.

About

Vinblastine is a potent vinca alkaloid antineoplastic agent derived from the Catharanthus roseus plant, commonly known as the periwinkle. Its primary mechanism of action involves binding to tubulin, a protein essential for the formation of microtubules, which are critical components of the mitotic spindle. By disrupting microtubule assembly, vinblastine effectively inhibits cell division, leading to metaphase arrest and subsequent apoptosis in rapidly proliferating cancer cells. This cytotoxic effect makes it a cornerstone in the treatment of various malignancies, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, advanced breast cancer, and testicular cancer. It is typically administered intravenously, often as a key component of multi-drug chemotherapy regimens, contributing significantly to disease control and improved patient survival rates in these aggressive cancers.

Uses

• Hodgkin's Lymphoma
• Non-Hodgkin's Lymphoma
• Testicular Cancer
• Breast Cancer

Directions For Use

Administer intravenously by a healthcare professional. Do not administer intrathecally.

Benefits

• Effective against various lymphomas
• Part of curative regimens for testicular cancer
• Can be used in advanced breast cancer
• Induces tumor regression
• Often used in combination chemotherapy
• Relatively lower neurotoxicity compared to vincristine

Side Effects

• Bone marrow suppression (leukopenia, thrombocytopenia)
• Nausea
• Vomiting
• Constipation
• Peripheral neuropathy (less common than vincristine)
• Jaw pain
• Hair loss (alopecia)
• Stomatitis
• Phlebitis at injection site
• Extravasation leading to tissue necrosis
• Malaise
• Muscle pain

Safety Measures

• Alcohol - No specific contraindication, but avoid excessive alcohol due to potential for exacerbating general malaise or liver stress.
• Pregnancy - Contraindicated due to teratogenic and embryotoxic effects; use effective contraception.
• Breastfeeding - Not recommended; discontinue breastfeeding during treatment.
• Liver - Use with caution and consider dose reduction in patients with significant hepatic impairment.
• Kidney - No specific dose adjustment for renal impairment, but monitor closely.
• Lung - Rare cases of acute shortness of breath and bronchospasm have been reported, especially when used with mitomycin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.